Stoneridge Investment Partners LLC Increases Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Stoneridge Investment Partners LLC grew its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 21.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 68,681 shares of the biotechnology company’s stock after purchasing an additional 12,063 shares during the period. Stoneridge Investment Partners LLC’s holdings in Precigen were worth $77,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PGEN. State Street Corp grew its holdings in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 29,253 shares during the period. LexAurum Advisors LLC grew its stake in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares during the period. Iridian Asset Management LLC CT increased its holdings in shares of Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 149,829 shares during the period. Finally, Stifel Financial Corp boosted its holdings in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after buying an additional 15,680 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Stock Performance

Shares of PGEN opened at $1.70 on Friday. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $1.93. The company has a 50-day moving average of $1.05 and a two-hundred day moving average of $1.03.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PGEN. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Precigen presently has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.